{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:20:24Z","timestamp":1793737224963,"version":"4.6.1"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy resistance in triple-negative breast cancer (TNBC) remains a critical clinical challenge. This review synthesizes and critically evaluates current evidence on two interconnected mechanisms that have emerged from recent research: the functional plasticity of mast cells (MCs) and metabolic reprogramming. Far from being mere allergic effectors, MCs exhibit high phenotypic diversity, with antigen-presenting MCs (apMCs) representing a unique subset identified in recent studies capable of priming anti-tumor T cell responses. A landmark phase 2 trial has demonstrated that modulation of apMCs can enhance responses to anti-PD-1 therapy in patients with ICI-refractory TNBC. However, within the TNBC TIME, metabolic dysregulation\u2014characterized by glycolytic flux, lactate accumulation, and lipid alterations\u2014skews MCs toward immunosuppressive phenotypes and suppresses apMC function. Published studies have documented that this bidirectional crosstalk forms a vicious cycle that sustains immune evasion and limits the efficacy of immune checkpoint inhibitors. To decipher this complexity, patient-derived organoid (PDO) models co-cultured with autologous immune cells have emerged as a validated platform that preserves tumor heterogeneity and enables real-time dissection of metabolism-immune circuits. This review systematically synthesizes current knowledge on the biological basis of MC plasticity, the metabolite-driven regulation of their function, and the utility of organoid-based systems for mechanistic discovery and drug screening. We critically evaluate emerging multidimensional therapeutic strategies, including pharmacological reprogramming of apMCs, metabolic normalization, and engineered cell therapies, and identify key knowledge gaps that must be addressed to translate these insights into clinical practice. By integrating advances in immuno-oncology, cancer metabolism, and bioengineering, this review provides a framework for translating current insights into clinically actionable strategies to overcome immunotherapy resistance in TNBC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1774946","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:45:58Z","timestamp":1779684358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming immunotherapy resistance in triple-negative breast cancer: a critical review of mast cell plasticity, metabolic reprogramming, and organoid models"],"prefix":"10.3389","volume":"17","author":[{"given":"Kunyuan","family":"He","sequence":"first","affiliation":[{"name":"Department of Thyroid Breast Surgery, The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia Autonomous Region, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast Surgery, The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia Autonomous Region, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Central Laboratory, The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia Autonomous Region, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[{"name":"The Central Laboratory, The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia Autonomous Region, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Thyroid Breast Surgery, The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia Autonomous Region, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-022-06665-6","article-title":"Clinical trials of immunotherapy in triple-negative breast cancer","volume":"195","author":"Howard","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1423924","article-title":"Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1153990","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630464","article-title":"Immunotherapy resistance in triple-negative breast cancer: molecular mechanisms, tumor microenvironment, and therapeutic implications","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: impassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (keynote-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020316","article-title":"A high-dimensional window into the micro-environment of triple negative breast cancer","volume":"13","author":"Nederlof","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1424237","article-title":"The role of metabolic reprogramming in immune escape of triple-negative breast cancer","volume":"15","author":"Bao","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.1092","article-title":"Update on mast cell biology","volume":"155","author":"Pahima","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-49270-0_9","article-title":"Mast cells in the tumor microenvironment","volume":"1273","author":"Aponte-L\u00f3pez","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00262-025-04054-8","article-title":"Mast cells-intestinal cancer cells crosstalk is mediated by tnf-alpha and sustained by the il-33\/st2 axis","volume":"74","author":"Dal Secco","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and pd-l1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03776-7","article-title":"Mobilizing antigen-presenting mast cells in anti-pd-1-refractory triple-negative breast cancer: a phase 2 trial","volume":"31","author":"Wu","year":"2025","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01304-w","article-title":"Targeting metabolism to enhance immunotherapy within tumor microenvironment","volume":"45","author":"Liang","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212223","article-title":"Metabolic reprogramming of immune cells in the tumor microenvironment","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-21-2807","article-title":"Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics","volume":"82","author":"Bhatia","year":"2022","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2025.05.011","article-title":"An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer","volume":"32","author":"Li","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.04.031","article-title":"Immune organoid for cancer immunotherapy","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.985861","article-title":"Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer","volume":"13","author":"Fang","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12429","article-title":"Single-cell atlas reveals a distinct immune profile fostered by t cell-b cell crosstalk in triple negative breast cancer","volume":"43","author":"Ding","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41698-024-00729-0","article-title":"Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12967-016-0925-6","article-title":"Expression of pd-l1 in triple-negative breast cancer based on different immunohistochemical antibodies","volume":"14","author":"Sun","year":"2016","journal-title":"J Transl Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13058-023-01724-2","article-title":"Comparison of sp142 and 22c3 pd-l1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","volume":"25","author":"Sigurjonsdottir","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of mhc class i antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into t cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of cd80 and cd86: a molecular basis for the cell-extrinsic function of ctla-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory t cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/itt.S495751","article-title":"Recent advances in immune checkpoint inhibitors for triple-negative breast cancer","volume":"14","author":"Corti","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.029","article-title":"Advances in mast cell biology","volume":"149","author":"Boyce","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022006969","article-title":"Single-cell transcriptomics reveals the identity and regulators of human mast cell progenitors","volume":"6","author":"Wu","year":"2022","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.12.011","article-title":"The return of the mast cell: new roles in neuroimmune itch biology","volume":"140","author":"Wang","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.03.007","article-title":"Mrgprx2 gain-of-function mutation drives enhanced mast cell reactivity in chronic spontaneous urticaria","volume":"156","author":"Ye","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.022","article-title":"Mast cells modulate macrophage biology through release of prestored csf1","volume":"156","author":"Kovacs","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216795","article-title":"Pgr-kitlg signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells","volume":"589","author":"Yang","year":"2024","journal-title":"Cancer Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1770","article-title":"Morphometric analysis of mast cells in tumor predicts recurrence of hepatocellular carcinoma after liver transplantation","volume":"5","author":"Rohr-Udilova","year":"2021","journal-title":"Hepatol Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.04.045","article-title":"Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment","volume":"171","author":"Baechle","year":"2022","journal-title":"Surgery"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111085","article-title":"Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer","volume":"27","author":"Ma","year":"2024","journal-title":"iScience"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1969075","article-title":"Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response","volume":"10","author":"Cao","year":"2021","journal-title":"Oncoimmunology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41419-023-06139-7","article-title":"Scf and il-33 regulate mouse mast cell phenotypic and functional plasticity supporting a pro-inflammatory microenvironment","volume":"14","author":"Molfetta","year":"2023","journal-title":"Cell Death Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.10.595","article-title":"MRGPRX2-mediated mast cell activation promotes malignant progression of cutaneous squamous cell carcinoma through IL-17A release","volume":"4","author":"Zhou","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08753-w","article-title":"Role of mast cells in shaping the tumor microenvironment","volume":"58","author":"Komi","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924244","article-title":"Dynamically upregulated mast cell Cpa3 patterns in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis","volume":"13","author":"Siddhuraj","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-022-00731-2","article-title":"New perspectives on the origins and heterogeneity of mast cells","volume":"23","author":"St John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030459","article-title":"The controversial role of intestinal mast cells in colon cancer","volume":"12","author":"Molfetta","year":"2023","journal-title":"Cells"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.02.040","article-title":"Mast cells activated in vitro can modulate macrophage polarization and antibacterial responses","volume":"156","author":"Holter","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s13770-022-00433-9","article-title":"Mast cells tryptase promotes intestinal fibrosis in natural decellularized intestinal scaffolds","volume":"19","author":"Wan","year":"2022","journal-title":"Tissue Eng Regener Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112411","article-title":"Signal transduction pathways activated by innate immunity in mast cells: Translating sensing of changes into specific responses","volume":"9","author":"Espinosa-Riquer","year":"2020","journal-title":"Cells"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.260964","article-title":"Ilt4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer","volume":"136","author":"Zhang","year":"2023","journal-title":"J Cell Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-20-4190","article-title":"Targeting pyruvate kinase M2 phosphorylation reverses aggressive cancer phenotypes","volume":"81","author":"Apostolidi","year":"2021","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2021.108366","article-title":"The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer","volume":"787","author":"Delgir","year":"2021","journal-title":"Mutat Res Rev Mutat Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114268","article-title":"Photothermal nanocomposite reactivate \"immune-hot\" for triple-negative breast cancer treatment via glutamine metabolism reprograming","volume":"245","author":"Cheng","year":"2025","journal-title":"Coll Surf B Biointerfaces"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00679-2","article-title":"Myc derived circrna promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism","volume":"14","author":"Wang","year":"2023","journal-title":"Discov Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217271","article-title":"Fabp4-mediated lipid metabolism promotes tnbc progression and breast cancer stem cell activity","volume":"604","author":"Yu","year":"2024","journal-title":"Cancer Lett"},{"key":"B65","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40779-023-00470-y","article-title":"Rarres2 regulates lipid metabolic reprogramming to mediate the development of brain metastasis in triple negative breast cancer","volume":"10","author":"Li","year":"2023","journal-title":"Mil Med Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1139\/bcb-2020-0439","article-title":"Metastatic tnbc is closely associated with a fused mitochondrial morphology and a glycolytic and lipogenic metabolism","volume":"99","author":"P\u00e9rez-Trevi\u00f1o","year":"2021","journal-title":"Biochem Cell Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.11.675705","article-title":"TRPML1 signaling at lysosomes-mitochondria nexus drives triple-negative breast cancer mitophagy, metabolic reprogramming and chemoresistance","volume":"16","author":"Syeda","year":"2025","journal-title":"bioRxiv"},{"key":"B68","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1186\/s12967-024-05692-9","article-title":"Identification of the metabolic protein Atp5mf as a potential therapeutic target of tnbc","volume":"22","author":"Chen","year":"2024","journal-title":"J Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15353","article-title":"Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating Egfr-Myc-Txnip axis: Potential therapeutic implications","volume":"288","author":"Iqbal","year":"2021","journal-title":"FEBS J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00428","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1061789","article-title":"Facts and perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer","volume":"12","author":"Schreier","year":"2022","journal-title":"Front Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218227","article-title":"Histone lactylation bridges metabolic reprogramming with chromatin-immune crosstalk in triple-negative breast cancer","volume":"639","author":"Li","year":"2026","journal-title":"Cancer Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200273","article-title":"Dietary cholesterol metabolite regulation of tissue immune cell development and function","volume":"209","author":"Frascoli","year":"2022","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-0174-0","article-title":"Cholesterol metabolism in cancer: Mechanisms and therapeutic opportunities","volume":"2","author":"Huang","year":"2020","journal-title":"Nat Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094644","article-title":"Tryptophan metabolites at the crossroad of immune-cell interaction via the aryl hydrocarbon receptor: Implications for tumor immunotherapy","volume":"22","author":"Gargaro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041547","article-title":"Immunometabolic maladaptations to the tumor microenvironment","volume":"14","author":"Hathaway","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331518","article-title":"A role of gut microbiota metabolites in Hla-E and Nkg2 blockage immunotherapy against tumors: New insights for clinical application","volume":"15","author":"Cheng","year":"2024","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1693954","article-title":"Mast cell metabolism in cancer: An underexplored frontier demanding more attention","volume":"16","author":"Frossi","year":"2025","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2025.5687","article-title":"Microbial short chain fatty acids: Effective histone deacetylase inhibitors in immune regulation (review)","volume":"57","author":"Wang","year":"2026","journal-title":"Int J Mol Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011899","article-title":"Tumor-infiltrating mast cells as potential chemoimmunotherapy enhancer in triple-negative breast cancer","volume":"13","author":"Fan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13290","article-title":"Cd8(+) T cell-related Kctd5 contributes to Malignant progression and unfavorable clinical outcome of patients with triple-negative breast cancer","volume":"30","author":"Li","year":"2024","journal-title":"Mol Med Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1204224","article-title":"Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes","volume":"14","author":"Graham","year":"2023","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e0334335","DOI":"10.1371\/journal.pone.0334335","article-title":"Molecular determinants of neoadjuvant chemotherapy resistance in breast cancer: An analysis of gene expression and tumor microenvironment","volume":"20","author":"Guevara-Nieto","year":"2025","journal-title":"PloS One"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-24-0693","article-title":"Depleting the action of Ezh2 through Pi3k-Mtor inhibition to overcome metastasis and immunotherapy resistance in triple-negative breast cancer","volume":"24","author":"Melino","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030773","article-title":"The role of patient-derived organoids in triple-negative breast cancer drug screening","volume":"11","author":"Psilopatis","year":"2023","journal-title":"Biomedicines"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101859","article-title":"The transformative role of 3d culture models in triple-negative breast cancer research","volume":"16","author":"Bittman-Soto","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13058-021-01461-4","article-title":"Evaluation of Fgfr targeting in breast cancer through interrogation of patient-derived models","volume":"23","author":"Chew","year":"2021","journal-title":"Breast Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"8406","DOI":"10.1038\/s41467-023-44162-6","article-title":"High-throughput deconvolution of 3d organoid dynamics at cellular resolution for cancer pharmacology with Cellos","volume":"14","author":"Mukashyaka","year":"2023","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00502-1","article-title":"Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer","volume":"9","author":"Echeverria","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2021.05.027","article-title":"Transgenic mouse models of breast cancer","volume":"516","author":"Regua","year":"2021","journal-title":"Cancer Lett"},{"key":"B93","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12032-025-02865-4","article-title":"Advancing breast cancer research: A comprehensive review of in vitro and in vivo experimental models","volume":"42","author":"Das","year":"2025","journal-title":"Med Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-024-03014-x","article-title":"Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: Implications for precision phototherapies","volume":"43","author":"Camorani","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.actbio.2025.12.026","article-title":"The effect of stiffness on cell behavior and drug resistance in patient-derived breast cancer organoids","volume":"210","author":"Jeong","year":"2026","journal-title":"Acta Biomater"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s12195-020-00625-0","article-title":"Organoids as complex in vitro models for studying radiation-induced cell recruitment","volume":"13","author":"Hacker","year":"2020","journal-title":"Cell Mol Bioeng"},{"key":"B97","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1186\/s12885-023-11362-8","article-title":"The Triplex study: Use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer","volume":"23","author":"Divoux","year":"2023","journal-title":"BMC Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.11.016","article-title":"Beyond classical immunity: Mast cells as signal converters between tissues and neurons","volume":"57","author":"Plum","year":"2024","journal-title":"Immunity"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1213320","article-title":"Mast cell-mediated immune regulation in health and disease","volume":"10","author":"Dileepan","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102509","article-title":"Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread","volume":"24","author":"Strelez","year":"2021","journal-title":"iScience"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr4831","article-title":"Acoustic virtual 3d scaffold for direct-interacting tumor organoid-immune cell coculture systems","volume":"10","author":"Shan","year":"2024","journal-title":"Sci Adv"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7740","article-title":"Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer","volume":"16","author":"Ding","year":"2024","journal-title":"Sci Transl Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004907","article-title":"Isocucurbitacin B targets STAT3 to induce ferroptosis and promote anti-PD1 immunotherapy responses in breast cancer","author":"Zhou","year":"2026","journal-title":"Int J Surg"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1244159","article-title":"Sulindac sulfide as a non-immune suppressive \u03b3-secretase modulator to target triple-negative breast cancer","volume":"14","author":"Hossain","year":"2023","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40364-025-00797-9","article-title":"Tumor-specific mhc-ii guides anthracycline exemption and immunotherapy benefit in breast cancer","volume":"13","author":"Wang","year":"2025","journal-title":"biomark Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj7808","article-title":"Interferon-induced senescent cd8(+) t cells reduce anti-pd1 immunotherapy efficacy in early triple-negative breast cancer","volume":"17","author":"Fu","year":"2025","journal-title":"Sci Transl Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202507975","article-title":"Decoy extracellular vesicles overcome triple-negative breast cancer heterogeneity via membrane-cytoplasm-mitochondria cascade targeting","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B108","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaci.2008.10.040","article-title":"Notch signaling confers antigen-presenting cell functions on mast cells","volume":"123","author":"Nakano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000483","article-title":"Mesothelin-targeted car-nk cells derived from induced pluripotent stem cells have a high efficacy in killing triple-negative breast cancer cells as shown in several preclinical models","volume":"46","author":"Yang","year":"2023","journal-title":"J Immunother"},{"key":"B110","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ dc-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12672-025-02320-w","article-title":"Inhibiting glycolysis facilitated checkpoint blockade therapy for triple-negative breast cancer","volume":"16","author":"Li","year":"2025","journal-title":"Discov Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-13-1091","article-title":"Inhibition of monocarboxylate transporter-1 (mct1) by azd3965 enhances radiosensitivity by reducing lactate transport","volume":"13","author":"Bola","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123568","article-title":"Chrono-controlled hydrogel platform orchestrates metabolic reprogramming and cuproptosis-driven immune activation against triple-negative breast cancer","volume":"325","author":"Lu","year":"2026","journal-title":"Biomaterials"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2147\/bctt.S496322","article-title":"Dysregulation of fatty acid metabolism in breast cancer and its targeted therapy","volume":"16","author":"Chang","year":"2024","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/nature17412","article-title":"Potentiating the antitumour response of cd8(+) t cells by modulating cholesterol metabolism","volume":"531","author":"Yang","year":"2016","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.158886","article-title":"Cox-1 dependent biosynthesis of 15-hydroxyeicosatetraenoic acid in human mast cells","volume":"1866","author":"Johnsson","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B117","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.Mct-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor cb-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115101","article-title":"Ginsenoside ck induces apoptosis in triple-negative breast cancer cells by targeting glutamine metabolism","volume":"202","author":"Zhang","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4180","article-title":"Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme","volume":"36","author":"Triplett","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001799","article-title":"Global biomarker trends in triple-negative breast cancer research: A bibliometric analysis","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003874","article-title":"Untargeted metabolomics based on LC-MS and GC-MS reveal metabolic reprogramming and putative biomarkers in amyotrophic lateral sclerosis","volume":"139","author":"Xu","year":"2026","journal-title":"Chin Med J (Engl)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13046-024-02980-6","article-title":"Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response","volume":"43","author":"Smabers","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13046-022-02561-5","article-title":"An organoid library of salivary gland tumors reveals subtype-specific characteristics and biomarkers","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2142559","article-title":"Combination immunotherapy strategies for triple-negative breast cancer: Current progress and barriers within the pharmacological landscape","volume":"15","author":"Uliano","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jvir.2023.09.035","article-title":"Locoregional therapies in immunologically \"cold\" tumors: Opportunities and clinical trial design considerations","volume":"35","author":"Msaouel","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-0970","article-title":"Targeting cholesterol biosynthesis with statins synergizes with akt inhibitors in triple-negative breast cancer","volume":"84","author":"Hillis","year":"2024","journal-title":"Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1453886","article-title":"Mitochondrial regulation in the tumor microenvironment: Targeting mitochondria for immunotherapy","volume":"15","author":"Ahn","year":"2024","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101176","article-title":"Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer","volume":"8","author":"Chen","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34931","article-title":"Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients","volume":"155","author":"Wu","year":"2024","journal-title":"Int J Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/s41467-020-19540-z","article-title":"Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17124","article-title":"Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment","volume":"26","author":"Li","year":"2022","journal-title":"J Cell Mol Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38732","article-title":"Identification of a panoptosis-related prognostic model in triple-negative breast cancer, from risk assessment, immunotherapy, to personalized treatment","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215322","article-title":"K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer","volume":"14","author":"Johnson","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-1703","article-title":"Modeling drug responses and evolutionary dynamics using patient-derived xenografts reveals precision medicine strategies for triple-negative breast cancer","volume":"85","author":"Shea","year":"2025","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1038\/s41598-024-83989-x","article-title":"Diffusion smart-seq3 of breast cancer spheroids to explore spatial tumor biology and test evolutionary principles of tumor heterogeneity","volume":"15","author":"Cougnoux","year":"2025","journal-title":"Sci Rep"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17244003","article-title":"The molecular landscape and utility of multiomic analyses in triple-negative breast cancer: Further subtyping and exploring novel biomarkers and therapeutic targets","volume":"17","author":"Juan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B137","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-025-00672-1","article-title":"Multi-omics analyses of the heterogenous immune microenvironment in triple-negative breast cancer implicate uqcrfs1 potentiates tumor progression","volume":"14","author":"Tang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1950","article-title":"Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer","volume":"16","author":"Cao","year":"2024","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:46:06Z","timestamp":1779684366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":138,"alternative-id":["10.3389\/fimmu.2026.1774946"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1774946","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1774946"}}